Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy - Wikidata - awgldk - TriplyDB

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

http://www.wikidata.org/entity/Q33836681

about

Highlight on advances in nontuberculous mycobacterial disease in North America.'"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection Mycobacterial endocarditis: a comprehensive review Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights Application of a stochastic modeling to assess the evolution of tuberculous and non-tuberculous mycobacterial infection in patients treated with tumor necrosis factor inhibitors Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries The epidemiology of pulmonary nontuberculous mycobacteria: data from a general hospital in Athens, Greece, 2007-2013.MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections.The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.Interferon alpha treatment of patients with impaired interferon gamma signaling.Mycobacterium avium complex cervical lymphadenitis in an immunocompetent adult.JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Host response to nontuberculous mycobacterial infections of current clinical importance.Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Atypical mycobacterial infection presenting as persistent skin lesion in a patient with ulcerative colitis.IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease.Mycobacterium chelonae bacteremia after first dose of infliximab for ulcerative colitis Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001-2011.Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.Modulation of innate host factors by Mycobacterium avium complex in human macrophages includes interleukin 17.Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area A case of erosive polyarthritis in a patient diagnosed with a suspicion of atypical mycobacteria.Nontuberculous mycobacterial pulmonary infections Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease.Infections associated with monoclonal antibody and fusion protein therapy in humans.Safety of biologic therapy in rheumatoid arthritis.Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review.Crohn's disease and the mycobacterioses: a quarter century later. Causation or simple association?Overview of safety of non-biologic and biologic DMARDs.Pulmonary disease caused by nontuberculous mycobacteria.Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Pulmonary Mycobacterium kansasii Infection Mimicking Malignancy on the (18)F-FDG PET Scan in a Patient Receiving Etanercept: A Case Report and Literature Review.Nontuberculous mycobacteria infections in immunosuppressed hosts.Association of Interferon-γ Receptor-1 Gene Polymorphism with Nontuberculous Mycobacterial Lung Infection among Iranian Patients with Pulmonary Disease.

P2860

Q27028191-AC2EA6FC-1265-482E-BE34-25C18D8E254B Q28070339-41D96A49-38C6-4275-BAAD-AAA11E969CA5 Q28080539-D6FFBFCC-029C-4EAD-B850-270760E38083 Q28083865-43DC7CC3-EEB9-4AB6-9236-DC9466550F39 Q28087593-41839385-EE75-4CE3-A89C-638514B458BD Q28485323-2C13DDD4-1DAF-46F4-BBCA-C72D0195FD7D Q28729217-DC17755D-23EB-4C3D-BAE8-5733BE07FC42 Q30843389-4FF828EA-9FCD-41AE-BEC0-92C6AF3648E4 Q33578979-8763DDBD-50E7-4F80-84D7-56EA4F37BE53 Q33829772-AA001294-10F8-4044-9B63-ED0A737067DD Q34059742-80325D6D-76D0-42C4-BC70-239AA8980E0B Q34150373-E1586D2C-4E6E-4F9E-B5E7-A4CF5DE38BF4 Q34276089-9078941B-9145-4A02-85B8-361F47C3E968 Q34298306-34BE407B-D122-4C4B-BD2C-BACC441F4B45 Q34643625-B6ADD566-2D0C-44B8-8727-58A1D7B5FFAC Q35103988-FB2BDECB-2A8C-4F30-AF1F-6F9F3D0331F3 Q35237588-72948273-54D5-43A7-9367-D8FBB9433F22 Q35293749-0D3858B9-0117-4A0C-985D-BF5ABA9F6BE0 Q35469357-5293998C-30CF-4B81-9E56-4D77B9A3263E Q35580958-7CC243E9-1A0A-4579-A05F-8A7D7C391E61 Q35896998-029655FC-2426-4EFA-AF4C-CAB203064853 Q36128623-F3E6B184-C74A-41BC-B7DE-6894B955287A Q36156072-5564024D-BD07-4784-B78B-942B64A0F579 Q36230244-D671AF5B-B906-45A8-A67D-DE8BED39A7E0 Q36253035-6F85F8AE-F0CF-4B30-9EE3-783EAB85B419 Q37086326-36BFE531-905B-4EF7-A54A-53CBDF978B6B Q37166008-BB8BB238-C976-4442-B0D1-96625C409BC2 Q37629532-76BEBC8F-0B27-4314-A0F5-EDDCEE90811C Q37676737-B6EE466C-E850-4F93-8181-C921571D2DA7 Q37912944-261239BA-7B0A-483A-BFCD-2EB446CB3264 Q37944433-4EB2A3E0-AB8F-4150-956E-4D84D6BDF0B3 Q37968488-F647D551-E2AE-48AE-AA7A-59EDDAEF3E35 Q37975540-FA762EBE-FDB8-4A97-A32A-410AC581EE0E Q38065768-7EAB67A7-8A69-4D2F-B708-4B8CD75AA2D7 Q38066978-0831D264-667E-48F3-AB9C-9E2305970F02 Q38116751-64A18F32-A45D-4AAA-A7A1-E22F6AF8F670 Q38192553-D2E115F6-8730-4011-B031-D9AA607B22EF Q38267397-6160FBB2-578F-45DC-AFDF-15001A68136E Q38353491-B08CFAD5-7323-4D64-B2DB-2FC6D25B7565 Q38673928-3E819285-1C52-4D4E-97C6-9BF06DB912A4

P2860

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

http://www.wikidata.org/entity/Q33836681

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@ast

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@en

type

label

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@ast

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@en

prefLabel

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@ast

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@en

P1433

Q33836681-EA3E7316-7751-489F-8766-E0879F557D07

P1476

Q33836681-FD17C50B-E8B2-449F-BD97-BAB896EA6163

P2093

Q33836681-06F06697-DE57-4155-97AD-6F15D71FFBE1

Q33836681-16BA8049-529C-4857-8585-0B37B2406269

Q33836681-5CA879A8-3264-497B-BCF4-03CB8894CA69

Q33836681-B5E8EDB2-39C3-42F8-AD15-49364E966AE2

Q33836681-F84F7F55-5D78-427E-8663-CD7038820C3F

P2860

Q33836681-0710E79F-AB12-40C9-9AD3-F044E885EE0A

Q33836681-0E9B394D-E810-48A9-992C-84728507E4BD

Q33836681-23DF344E-1DDF-4DAE-98B6-AC03DB249342

Q33836681-2E51B584-E85E-4C4A-A5C9-005EF99DE6E1

Q33836681-41BD425C-D285-4EAB-A39B-F487CDFA890B

Q33836681-477BB7EC-3B0E-4442-BA8C-8C8756D58B84

Q33836681-4CCB8B42-D9B6-433A-A83F-E3C270BF6E33

Q33836681-4E8FF9F2-E796-45AF-BB91-B138B1ED0119

Q33836681-4F208018-B71F-4733-B05B-8024122F6B8F

Q33836681-68BC2D2C-142E-49AD-91FE-CE866C0F00C1

P304

Q33836681-9093574E-0E50-4E2B-BF4E-C44D4F5CF035

P31

Q33836681-0EA98407-DC0B-451F-BE4A-B9CC44AA3A30

Q33836681-A44581ED-AD62-49E2-B600-ABFDF7BA4E45

P356

Q33836681-D64AF348-A172-40DB-933D-8EC1121A0894

P433

Q33836681-A33502B5-14AC-4762-96C4-9AA3A9C42DEE

P478

Q33836681-219FF8B6-076E-44C7-A288-C3BC94B25065

P577

Q33836681-36819F04-111C-4023-BAFD-6F06CEED7F6F

P5875

Q33836681-60569C8E-AA4D-42F3-B32D-75D29CF07EC1

P698

Q33836681-3117052A-AC83-4D49-8CAF-0E54F4AD4C21

P921

Q33836681-669ABB89-0D21-4C1B-B410-3CB03599E678

Q33836681-6DABA71F-771F-4326-A3B1-1A63A7358327

Q33836681-6F25A35B-9332-4AFE-92A5-C7264BC60F79

Q33836681-8F1ED238-3C87-43B3-8FC9-2E1ED936A9AB

Q33836681-B0CB518D-8D3D-4DAA-996F-57564028DF15

P932

Q33836681-1A1323EC-4DB0-45FD-855F-CCD1A13A76DF

P356

P1433

Emerging Infectious Diseases

P1476

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

@en

P2093

Eric Chang

http://www.w3.org/2001/XMLSchema#string

Kevin L Winthrop

http://www.w3.org/2001/XMLSchema#string

Michael F Iademarco

http://www.w3.org/2001/XMLSchema#string

Philip A LoBue

http://www.w3.org/2001/XMLSchema#string

Shellie Yamashita

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

Nontuberculous mycobacteria in the environment.

The epidemiology of rheumatoid arthritis.

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

Defects in the interferon-gamma and interleukin-12 pathways.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

P304

1556-1561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID1510.090310

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38040258

http://www.w3.org/2001/XMLSchema#string

P698

19861045

http://www.w3.org/2001/XMLSchema#string

P921

Tumor necrosis factor

mycobacterium infectious disease

P932

2866401

http://www.w3.org/2001/XMLSchema#string